Get the Stockscreener App
2.07
0.98%
0.02
After Hours:
2.05
-0.02
-0.97%
Immutep Limited Adr Stock (IMMP) Latest News
Immutep Limited (NASDAQ:IMMP) Shares Sold by Jane Street Group LLC - Defense World
Verition Fund Management LLC Has $57,000 Stock Position in Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - The Manila Times
Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761 - GlobeNewswire Inc.
Immutep shares new cancer study results - Investing.com
Immutep Quarterly Activities Report Q1 FY25 - GlobeNewswire
Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial - The Manila Times
Immutep Limited ADR (IMMP) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Metric Deep Dive: Understanding Immutep Limited ADR (IMMP) Through its Ratios - The Dwinnex
Immutep reports positive results in cancer study - Investing.com
Dow Jumps Over 200 Points; NY Empire State Manufacturing Index Increases In September - Benzinga
Research Analysts Issue Forecasts for Immutep Limited’s FY2025 Earnings (NASDAQ:IMMP) - Defense World
Immutep Limited ADR (IMMP) Stock: Navigating a Year of Volatility - The InvestChronicle
Short Interest in Immutep Limited (NASDAQ:IMMP) Declines By 10.1% - Defense World
Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody - GlobeNewswire
Virtu Financial LLC Buys 32,864 Shares of Immutep Limited (NASDAQ:IMMP) - Defense World
Immutep reports steady progress in Q4 FY24 - Investing.com India
Immutep reports steady progress in Q4 FY24 By Investing.com - Investing.com Australia
Immutep Limited (NASDAQ:IMMP) Shares Acquired by BNP Paribas Financial Markets - Defense World
Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer - GlobeNewswire
FY2027 EPS Estimates for Immutep Limited (NASDAQ:IMMP) Cut by Capital One Financial - American Banking and Market News
Equities Analysts Set Expectations for Immutep Limited’s FY2029 Earnings (NASDAQ:IMMP) - American Banking and Market News
Immutep Limited (NASDAQ:IMMP) Short Interest Up 6.2% in June - American Banking and Market News
Immutep Receives Regulatory Clearance for Phase I Study of - GlobeNewswire
Baird cuts Immutep stock target on phase 2b trial results, retains Outperform - Investing.com
Stocks of the Hour: Adherium, Nanoveu, Nimy Resources - ShareCafe
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 - GlobeNewswire
10 Best Australian Stocks To Buy - Yahoo Finance
Immutep LimitedADR (IMMP) Price Target Increased by 7.83% to 2.80 - MSN
Immutep Announces GMP Manufacturing Process Developed for - GlobeNewswire
Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations - Stockhead
FDA Grants Fast Track Designation to 1L Eftilagimod Alpha for Recurrent or Metastatic HNSCC - Targeted Oncology
The Daily Biotech Pulse: Moderna To Kickstart Phase 3 Study On July 27, Immutep Awarded Antibody Patent - Yahoo Finance
Immutep Ltd (IMMP) Stock Price, Trades & News - GuruFocus.com
Benzinga's Daily Biotech Pulse: Organovo Falls On Earnings; Celgene Gets New CFO - Yahoo Finance
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):